CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Embark | D5241C00006
Sponsor: AstraZenca
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).
Endura | GSK 222714
Sponsor: GlaxoSmithKline (GSK)
Depemokimab is being developed as a treatment for individuals with moderate to severe COPD. The aim of this study is to assess the efficacy and safety of depemokimab compared as an add-on medicine in participants with uncontrolled moderate to severe COPD with type 2 inflammation.
Verona 212 | RPL554-CO-212
Sponsor: Verona Pharma
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).
Presto | D7860C00006
Sponsor: AstraZenca
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 3 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Pfizer | C4531031
Sponsor: Pfizer
An interventional phase 2/3, randomized, double-blind, third party-unblinded, placebo-controlled, parallel-group study to investigate efficacy and safety of pf-07275315 in adult participants with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Interested in Learning More About COPD Trials?
Submit your information and our team will follow up within 24–48 hours.
What Can I Expect if I Enroll?
If you are interested in learning more or enrolling, our staff will contact you within a few days.
There is no obligation, and your information will be kept confidential. Our staff will:
- Screen interested participants for eligibility in active clinical trials
- Determine whether you may qualify for participation
- Explain study details, including protocol, duration, and compensation (varies by study)
- Provide clear guidance on the study process from start to finish and answer any questions
- Communicate with your established physician, as appropriate, regarding your participation
- Patient enrollment and participation are voluntary and may be discontinued at any time
Patients enrolled in our clinical trials remain under the care of their established physician for routine healthcare.
Simply provide your contact information, and our staff will guide you through the next steps.